^
Association details:
| Biomarker: | ERCC1 overexpression |
|---|---|
| Cancer: | Soft Tissue Sarcoma |
| Drug: | Yondelis (trabectedin) (Alkylating agent, DNA inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
CUL4A, ERCC5, and ERCC1 as Predictive Factors for Trabectedin Efficacy in Advanced Soft Tissue Sarcomas (STS): A Spanish Group for Sarcoma Research (GEIS) Study
Published date:
04/30/2020
Excerpt:
Amongst the transcripts analyzed, high expression of ERCC1 was the most significantly associated with longer PFS on trabectedin plus doxorubicin arm (...p = 0.006). Likewise, high expression of ERCC5 (...p = 0.039) and of CUL4A (...p = 0.038) were all associated with better PFS on the experimental group...
Secondary therapy:
doxorubicin hydrochloride
DOI:
10.3390/cancers12051128
